Riccardo Panicucci

Rick Panicucci serves as the Chief Technology Officer of CMC and Senior Vice President of CMC at BridgeBio since May 2018. Prior experience includes Senior Vice President CMC roles at QED Therapeutics and Origin Biosciences, as well as Vice President of Pharmaceutical Development and Business Development at STA Pharmaceutical Co., Ltd. from February 2015 to April 2018. Prior to that, Rick held the position of Global Head of Chemical and Pharmaceutical Profiling at Novartis from January 2004 to February 2015 and was Director of Pharmaceutical Development at Vertex Pharmaceuticals between January 1997 and December 2003. The career began at Biogen as a Senior Scientist from January 1995 to December 1996. Educational qualifications include a Ph.D. in Chemistry from the University of Toronto (1983-1987) and a BS in Chemistry from McMaster University (1979-1983).